Erik Atkisson - 26 Jan 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Reporting relationship: GC & Chief Compliance Officer
Issuer ticker: N/A
Reported as of: 26 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jan 2023, 20:15:13 UTC
Prior SEC filing: 11 Mar 2022
Next SEC filing: 03 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Erik Atkisson

Key filing fact

Erik Atkisson filed Form 4 for Eiger BioPharmaceuticals, Inc. on 30 Jan 2023.

Key facts

This page summarizes Erik Atkisson's Form 4 filing for Eiger BioPharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jan 2023, 20:15.

Change

Previous filing in this sequence was filed on 11 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EIGR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +26,750
Change %
Price: $0.000000
Shares after: 26,750
Date: 26 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,750
Exercise price: $1.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 50% on the first anniversary of the January 26, 2023 grant date, and as to the remaining 50% on June 26, 2024, subject to the Reporting Person's continuous service as of each such date. The option vests in full upon a change in control of the Issuer.